Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 19, 2024
Daily News
February 19, 2024
- Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
- JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
February 19, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- MHLW Announces Revised Rule for Info Disclosure of Physician Payments
February 19, 2024
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Vital KSK, 3 Other Firms Invest in LinDo to Drive Japan Launch of Innovative Drugs
February 19, 2024
- 12 VEGF Inhibitors Ordered to Add Artery Dissection Risk to ADR List
February 19, 2024
- Astellas, Kelonia Join Hands to Develop In Vivo Cell Therapies
February 19, 2024
- UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
- Sandoz Launches Promotion for Humira Biosimilar in Japan
February 19, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Otsuka’s IgA Nephropathy Drug Gets FDA Breakthrough Tag
February 19, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…